Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

Phase 4

Completed

Conditions: Major Depression
Temporal Lobe Epilepsy

Interventions: Drug: placebo
Drug: escitalopram

First Posted Date: 2008-01-16

Last Posted Date: 2011-07-18

Lead Sponsor: Conrad, Erich J., M.D.

Target Recruit Count: 8

Registration Number: NCT00595699

Locations: 🇺🇸
LSU Anxiety and Mood Disorders Clinic, New Orleans, Louisiana, United States

Dementia Antipsychotics And Antidepressants Discontinuation Study

Phase 4

Completed

Conditions: Dementia

Interventions: Drug: Risperidone
Drug: Escitalopram
Drug: Citalopram
Drug: Sertraline
Drug: Paroxetine

First Posted Date: 2008-01-15

Last Posted Date: 2011-02-23

Lead Sponsor: Sykehuset Innlandet HF

Target Recruit Count: 149

Registration Number: NCT00594269

Locations: 🇳🇴
Sykehuset Innlandet HF, Reinsvoll, Oppland, Norway
🇳🇴
Diakonihjemmets Hospital, Oslo, Norway
🇳🇴
Ullevaal University Hospital, Oslo, Norway

and more 5 locations

Responses of Myocardial Ischemia to Escitalopram Treatment

Phase 4

Completed

Conditions: Myocardial Ischemia

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2007-12-17

Last Posted Date: 2015-08-05

Lead Sponsor: Duke University

Target Recruit Count: 127

Registration Number: NCT00574847

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Escitalopram
Drug: JNJ-18038683

First Posted Date: 2007-12-03

Last Posted Date: 2014-08-06

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 67

Registration Number: NCT00566202

Efficacy of Escitalopram in the Treatment of Internet Addiction

Phase 4

Completed

Conditions: Internet Addiction

Interventions: Drug: Escitalopram

First Posted Date: 2007-11-30

Last Posted Date: 2008-05-28

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 31

Registration Number: NCT00565422

Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene

Not Applicable

Completed

Conditions: Pharmacokinetics

Interventions: Drug: escitalopram

First Posted Date: 2007-10-30

Last Posted Date: 2019-03-27

Lead Sponsor: Max-Planck-Institute of Psychiatry

Target Recruit Count: 79

Registration Number: NCT00550485

Locations: 🇩🇪
Max Planck Institute of Psychiatry, Munich, Germany

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

Phase 4

Completed

Conditions: Depression

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2007-09-27

Last Posted Date: 2023-09-21

Lead Sponsor: University of Nebraska

Target Recruit Count: 160

Registration Number: NCT00536172

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: saredutant (SR48968)
Drug: escitalopram
Drug: placebo

First Posted Date: 2007-09-19

Last Posted Date: 2016-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 643

Registration Number: NCT00531622

Locations: 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Phase 4

Terminated

Conditions: PMS

Interventions: Drug: escitalopram
Other: placebo

First Posted Date: 2007-08-31

Last Posted Date: 2014-06-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 11

Registration Number: NCT00523705

Locations: 🇺🇸
Dept OB/GYN, Mudd Professorship Suite, Philadelphia, Pennsylvania, United States

Does Dual Therapy Hasten Antidepressant Response?

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: escitalopram + bupropion
Drug: bupropion extra long (XL)
Drug: escitalopram

First Posted Date: 2007-08-22

Last Posted Date: 2017-10-04

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 245

Registration Number: NCT00519428

Locations: 🇨🇦
University of Ottawa, Institute of Mental Health Research, Ottawa, Ontario, Canada
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy